Motor deficits, including problems with balance skills and gait or walking speed, are linked with non-motor symptoms of cognition — such as verbal fluency, memory, and attention — in people with Parkinson’s disease, a recent study suggests. Researchers believe these findings may help to identify cognitive deficits and…
Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference. Deep brain stimulation (DBS) can lessen motor function impairments and reduce the need for medication for up to 10 years in…
People with Parkinson’s disease have an altered perception of movement when viewing abstract art as compared with their age- and education-matched healthy peers, a study found. These results suggest that motor responses, aesthetic appreciation, and motion are somehow linked — and that altered neurological function, such as that observed…
Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. People with Parkinson’s disease are using more cannabis-based products, especially those containing cannabidiol (CBD), as a treatment option to ease…
The nonprofit Parkinson Canada has teamed up with technology company Catalyst to enhance awareness of available digital health tools that can help people with Parkinson’s disease keep up their medication regimen. People diagnosed with Parkinson’s usually require treatment with multiple medications, often with frequent dosing, to adequately…
Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Carbidopa/levodopa enteral suspension (CLES) provided long-term, sustained, and clinically meaningful reductions in “off” time for people with Parkinson’s disease, according…
PhotoPharmics plans to open, possibly this summer, a pivotal Phase 3 clinical trial of its light-based and noninvasive Celeste device in treating Parkinson’s symptoms, for use by patients at home and with trial goals evaluated using telemedicine. A particular company goal for this device, PhotoPharmics also announced, is reaching underserved patients…
New research suggests that brain inflammation is the likely reason antibody-based therapies are ineffective in clinical trials for people with Parkinson’s and Alzheimer’s diseases. The findings show that the binding of the antibody to its target protein — in the case of Parkinson’s disease the misfolded alpha-synuclein —…
Inbrain Neuroelectronics has raised $16.8 million in Series A financing to support moving into clinical testing a new neuromodulation device that uses computer learning to treat Parkinson’s disease and epilepsy. Electrodes for this next-generation neurostimulator are also based on graphene, a single layer of tightly bound carbon atoms that allows…
The National Institutes of Health (NIH) has awarded a $5 million grant to researchers investigating whether an artificial intelligence tool might improve the accuracy of diagnosing Parkinson’s disease at its early stages. Early diagnosis is challenging due to the overlap of Parkinson’s motor and non-motor symptoms and those of two…
Get regular updates to your inbox.